Suresh I Prajapati1, Aoife Kilcoyne1,2, Aislynn K Samano1, Dustin P Green1, Steven D McCarthy1, Barron A Blackman1, Michelle M Brady1, Lee Ann Zarzabal3, Arun K Tatiparthi4, Timothy J Sledz4, Timothy Duong5, Sachiko Ohshima-Hosoyama1, Francis J Giles2, Joel E Michalek3, Brian P Rubin6, Charles Keller7,8,9. 1. Greehey Children's Cancer Research Institute, University of Texas Health Science Center, 8403 Floyd Curl Drive, MC-7784, San Antonio, TX, 78229, USA. 2. Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl, San Antonio, TX, 78229, USA. 3. Epidemiology and Biostatistics, University of Texas Health Science Center, 7703 Floyd Curl, San Antonio, TX, 78229, USA. 4. Microphotonics Inc., Allentown, PA, USA. 5. Research Imaging Institute, University of Texas Health Science Center, 7703 Floyd Curl, San Antonio, TX, 78229, USA. 6. Department of Anatomic Pathology, Cleveland Clinic, Taussig Cancer Center and the Lerner Research Institute, Cleveland, OH, USA. 7. Greehey Children's Cancer Research Institute, University of Texas Health Science Center, 8403 Floyd Curl Drive, MC-7784, San Antonio, TX, 78229, USA. keller@ohsu.edu. 8. Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl, San Antonio, TX, 78229, USA. keller@ohsu.edu. 9. Pediatrics University of Texas Health Science Center, 7703 Floyd Curl, San Antonio, TX, 78229, USA. keller@ohsu.edu.
Abstract
PURPOSE: The purpose of this paper is to validate a rapid and cost-effective ex vivo technique, microCT-based virtual histology, as an alternative to MRI imaging for assessing the therapeutic response in genetically engineered mouse models of cancer. PROCEDURES: All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Health Science Center at San Antonio. MRI imaging was performed on 6-week-old, bortezomib-treated genetically engineered Patched1, p53 mice that recapitulate the characteristics of human medulloblastoma. After MRI scans, the same mice were euthanized to collect brain or spine samples for virtual histology staining followed by microCT scanning. RESULTS: Nine-micrometer resolution ex vivo micro X-ray computed tomography (microCT)-based virtual histology images were qualitatively reflective of high-field live animal images obtained with magnetic resonance imaging (MRI) and histopathology. Cerebellar volumes on microCT-based virtual histology correlated closely with MRI cerebellar volumes (R = 0.998). MRI and microCT-based virtual histology both indicated a significant difference between cerebellar volumes of untreated and treated mice (p = 0.02 and p = 0.04, respectively). The ex vivo microCT method also allowed a 7,430-fold improvement in voxel resolution (voxel volume of 729 μm³ for 9-μm isometric resolution microCT vs. 5,416,800 μm³ for 400 × 111 × 122 μm resolution MRI) at a 28% cost savings ($400 vs. $555 per animal). CONCLUSION: The ex vivo, en bloc technique of microCT-based virtual histology matched MRI in reflecting histopathology. MicroCT-based virtual histology proved to be a more cost-effective technique and less labor-intensive. On the other hand, MRI provides ability to perform in vivo imaging, faster scanning and lower radiation dose by sacrificing the spatial resolution. Thus, both in vivo MRI and ex vivo microCT-based virtual histology are effective means of quantitatively evaluating therapeutic response in preclinical models of cerebellar tumors including the childhood cancer, medulloblastoma.
PURPOSE: The purpose of this paper is to validate a rapid and cost-effective ex vivo technique, microCT-based virtual histology, as an alternative to MRI imaging for assessing the therapeutic response in genetically engineered mouse models of cancer. PROCEDURES: All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Health Science Center at San Antonio. MRI imaging was performed on 6-week-old, bortezomib-treated genetically engineered Patched1, p53mice that recapitulate the characteristics of humanmedulloblastoma. After MRI scans, the same mice were euthanized to collect brain or spine samples for virtual histology staining followed by microCT scanning. RESULTS: Nine-micrometer resolution ex vivo micro X-ray computed tomography (microCT)-based virtual histology images were qualitatively reflective of high-field live animal images obtained with magnetic resonance imaging (MRI) and histopathology. Cerebellar volumes on microCT-based virtual histology correlated closely with MRI cerebellar volumes (R = 0.998). MRI and microCT-based virtual histology both indicated a significant difference between cerebellar volumes of untreated and treated mice (p = 0.02 and p = 0.04, respectively). The ex vivo microCT method also allowed a 7,430-fold improvement in voxel resolution (voxel volume of 729 μm³ for 9-μm isometric resolution microCT vs. 5,416,800 μm³ for 400 × 111 × 122 μm resolution MRI) at a 28% cost savings ($400 vs. $555 per animal). CONCLUSION: The ex vivo, en bloc technique of microCT-based virtual histology matched MRI in reflecting histopathology. MicroCT-based virtual histology proved to be a more cost-effective technique and less labor-intensive. On the other hand, MRI provides ability to perform in vivo imaging, faster scanning and lower radiation dose by sacrificing the spatial resolution. Thus, both in vivo MRI and ex vivo microCT-based virtual histology are effective means of quantitatively evaluating therapeutic response in preclinical models of cerebellar tumors including the childhood cancer, medulloblastoma.
Authors: Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: Hernan G Martinez; Suresh I Prajapati; Carlos A Estrada; Fabio Jimenez; Marlon P Quinones; Isabel Wu; Ali Bahadur; Allen Sanderson; Christopher R Johnson; Minsub Shim; Charles Keller; Seema S Ahuja Journal: Circulation Date: 2009-09-01 Impact factor: 29.690
Authors: Aislynn K Samano; Sachiko Ohshima-Hosoyama; Thomas G Whitney; Suresh I Prajapati; Aoife Kilcoyne; Eri Taniguchi; William W Morgan; Laura D Nelon; Ai-Ling Lin; Osamu Togao; Inkyung Jung; Brian P Rubin; Brent M Nowak; Timothy Q Duong; Charles Keller Journal: Transgenic Res Date: 2010-01-27 Impact factor: 2.788
Authors: Eri Taniguchi; Min Jung Cho; Benjamin R Arenkiel; Mark S Hansen; Omar J Rivera; Amanda T McCleish; Stephen J Qualman; Denis C Guttridge; Matthew P Scott; Mario R Capecchi; Charles Keller Journal: Pediatr Blood Cancer Date: 2009-08 Impact factor: 3.167
Authors: John T Johnson; Mark S Hansen; Isabel Wu; Lindsey J Healy; Christopher R Johnson; Greg M Jones; Mario R Capecchi; Charles Keller Journal: PLoS Genet Date: 2006-04-28 Impact factor: 5.917
Authors: Sachiko Ohshima-Hosoyama; Monika A Davare; Suresh I Prajapati; Jinu Abraham; Sangeet Lal; Laura D Nelon; Aoife Kilcoyne; Francis J Giles; Martha A Hanes; Brian P Rubin; Charles Keller Journal: J Pediatr Hematol Oncol Date: 2012-03 Impact factor: 1.289
Authors: Vasileios Askoxylakis; Mark Badeaux; Sylvie Roberge; Ana Batista; Ned Kirkpatrick; Matija Snuderl; Zohreh Amoozgar; Giorgio Seano; Gino B Ferraro; Sampurna Chatterjee; Lei Xu; Dai Fukumura; Dan G Duda; Rakesh K Jain Journal: Nat Protoc Date: 2017-10-05 Impact factor: 13.491
Authors: David J Lloyd; Joan Helmering; Stephen A Kaufman; James Turk; Matt Silva; Sergio Vasquez; David Weinstein; Brad Johnston; Clarence Hale; Murielle M Véniant Journal: PLoS One Date: 2011-04-18 Impact factor: 3.240